Hematology-focused Disc Medicine has agreed to pay a $10 million down payment to Mabwell Therapeutics to develop and commercialize a portfolio of monoclonal antibodies for blood disorders.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,